Search alternatives:
teer decrease » greater decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 wt » 2 wt (Expand Search), 1 wt (Expand Search)
teer decrease » greater decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 wt » 2 wt (Expand Search), 1 wt (Expand Search)
-
17561
-
17562
-
17563
-
17564
-
17565
Figure S1 - E2A Predicts Prognosis of Colorectal Cancer Patients and Regulates Cancer Cell Growth by Targeting miR-320a
Published 2014“…Right: Change of E2A expression in SW480 cells after transfection of shE2A, E12 or E47: shE2A reduced the expression of E2A in SW480, while E12 and E47 increased E2A expression in SW480/shE2A cells, relative to the controls; (B) Transfection of E12 or E47 inhibited SW480/WT cell growth; (C) E2A regulates cell growth in NCM460 cells; (D) Transfection of E12 or E47 increased G<sub>0</sub>/G<sub>1</sub> phase of SW480/WT cells and decreased the S phase; (E) E2A regulates cell cycle progression in NCM460 cells; (F) Transfection of E12 or E47 upregulated the expression of miR-320a, compared to negative control. …”
-
17566
-
17567
Metformin does not further increase the median lifespan of DR-constitutive mutant eat-2, and metformin treatment triggers several DR phenotypes in wild-type <i>C. elegans</i> witho...
Published 2010“…<p><b>A.</b> Survival curves of <i>eat-2(ad1116)</i> mutants raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin plates at 20°C. …”
-
17568
Regulation of MCF-7 mammosphere formation by breast cancer promoters and metformin.
Published 2011“…On the other hand, metformin treatment decreased MCF-7 proliferation (mean ± SD, n = 3). *, <i>P</i><0.05; **, <i>P</i><0.01; ***, <i>P</i><0.001. …”
-
17569
-
17570
Variation of average codeword length (ACL) by number of edges.
Published 2020“…A positive variation indicates a decrease in the ACL. …”
-
17571
Complementary conditioning measures across the clinical study groups.
Published 2024“…CS<sup>+</sup> (F<sub>(1, 50)</sub> = 5.2, <i>P</i> = 0.03), with a no significant effects for Group (F<sub>(2, 50)</sub> = 0.1, <i>P</i> = 0.9) nor for interaction (F<sub>(2, 50)</sub> = 0.9, <i>P</i> = 0.4). …”
-
17572
-
17573
-
17574
-
17575
-
17576
Scutellarin’s Cardiovascular Endothelium Protective Mechanism: Important Role of PKG-I<i>α</i>
Published 2015“…The activation of PKG–1α was then studied using targeted proteomic analysis (MRM-MS) checking the phosphorylation state of the autophosphorylation domain (aa42-94). Significant decrease in phosphorylation of PKG-Iα at Ser50, Ser72, Ser89 was induced by HR injury while SCU treatment significantly increased the phosphorylation of PKG-Iα, not only at Ser50, Ser72 and Ser89, but also at Ser44 and Thr58 (two novel phosphorylation domains). …”
-
17577
Histone deacetylase (HDAC) inhibitor assessment.
Published 2016“…ITF 2357, an HDAC inhibitor which is structurally and functionally similar to SAHA, produced a dose-response curve with IC<sub>50</sub> of 0.2 μM. …”
-
17578
Plk1 inhibition suppresses the clonogenic potential of SUM149 and SUM159.
Published 2019“…(B) EC<sub>50</sub> was defined as 50% colony inhibition. Single agents EC<sub>50</sub> were reported for each TNBC cell line and drug. …”
-
17579
Image2_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg
Published 2024“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”
-
17580
Image1_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg
Published 2024“…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”